# Does Nebraska Medicaid Cover Wegovy or Zepbound? Heritage Health GLP-1 Rules By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-11-07 Canonical page: https://glpwatchdog.org/research/nebraska-medicaid-glp1-coverage > Nebraska Medicaid and its Heritage Health plans do not pay for weight-control drugs. State forms cover Wegovy for heart risk at ages 45 to 74 or MASH, and Zepbound for sleep apnea, after six months of supervised weight care. Criteria, renewals and appeal deadlines. ## Key points - A Nebraska regulation bars Medicaid payment for drugs prescribed for weight control. - Wegovy for heart risk is limited to ages 45 to 74, with no diabetes and an A1C under 6.5%. - Wegovy for MASH needs a recent scan, blood test or biopsy showing F2 or F3 scarring, and allows diabetes if Ozempic came first. - Zepbound for sleep apnea needs failed or unsuitable CPAP and oral appliance therapy and steady PAP use. - All three routes require six months in a supervised weight program; Nebraska Total Care uses the same criteria. No. As of November 2026, Nebraska Medicaid, including its Heritage Health plans, does not pay for Wegovy, Zepbound or any drug prescribed for weight control.[1] Its prior authorization forms do cover Wegovy to cut heart risk in adults aged 45 to 74 or to treat the liver disease MASH, and Zepbound for moderate to severe sleep apnea, each only after six months in a medically supervised weight program.[2][3] > **About this article.** This page reads Nebraska’s pharmacy regulation, the state’s fee-for-service prior authorization forms for Wegovy (last reviewed January 2026) and Zepbound (last revised July 2025), the drug list updated November 2, 2026, and one Heritage Health plan’s Wegovy policy, as they stood on November 7, 2026. We could not read the other two plans’ criteria or a Nebraska rule that states the fair hearing deadline. To compare states, try the [state Medicaid GLP-1 checker](https://glpwatchdog.org/tools/state-medicaid-glp1-checker). ## Will Nebraska Medicaid pay for Wegovy or Zepbound to lose weight? It will not. Nebraska’s pharmacy rules list drugs “prescribed or recommended for weight control or appetite suppression” among the items Medicaid will not pay for.[1] The state forms repeat the point in their own way: the Zepbound form says the drug is covered only for sleep apnea, and the Wegovy form names heart risk and MASH as its two covered uses.[2][3] Neither drug appears on the November 2026 preferred drug list.[4] Under federal law, states may exclude weight-loss drugs from Medicaid, and Nebraska is one of many that do.[10] Our explainer on [why Medicaid pays for Ozempic but not Wegovy](https://glpwatchdog.org/research/does-medicaid-cover-ozempic-and-wegovy) covers the federal background. ## Do Heritage Health plans follow the same rules? As far as we could read, yes. Heritage Health, the state’s Medicaid managed care program, runs through three plans: Nebraska Total Care, Molina and UnitedHealthcare Community Plan.[6] Nebraska Total Care’s Wegovy policy for its Medicaid members uses the state’s criteria nearly word for word, including the age range, the A1C limit and the six-month program.[5][2] We did not find published Wegovy or Zepbound criteria for the other two plans, so members of those plans should ask the plan for its form. The state forms in this article are written for fee-for-service members and send requests to Prime Therapeutics, the state’s pharmacy contractor.[2] ## Which GLP-1 uses does Nebraska Medicaid cover? *Nebraska Medicaid GLP-1 routes, from the fee-for-service Wegovy form (January 2026), Zepbound form (July 2025) and drug list (November 2026)* | Use | Drug | Main requirements | First approval | | --- | --- | --- | --- | | Weight control alone | Wegovy, Zepbound | Not covered | None | | Type 2 diabetes | Ozempic, Trulicity, Victoza preferred; Mounjaro and Ozempic tablets non-preferred | Diabetes plus a metformin trial, or diabetes with heart and artery disease | Per drug list | | Heart attack and stroke risk | Wegovy injection or tablets | Age 45 to 74; no diabetes and A1C under 6.5%; BMI 27+ with a condition or 30+; past heart attack, stroke or symptomatic artery disease; 6-month program | 6 months | | MASH with F2 or F3 fibrosis | Wegovy injection | Age 18+; recent FibroScan, MRE, ELF test or biopsy; liver, GI or diabetes specialist; Ozempic tried first if diabetic; 6-month program | 6 months | | Moderate to severe sleep apnea | Zepbound | Age 18+; no diabetes and A1C under 6.5%; BMI 30+; AHI 15+; PAP and oral appliance failed, not tolerated or unsuitable; sleep specialist; 6-month program | 6 months | The six-month program is the step people most often lack. For each route, the form asks whether the patient has finished at least six months of weight management supervised by a physician, nurse practitioner or physician assistant, covering behavior change, a reduced-calorie diet and more activity.[2][3] A note in the chart that the patient was told to diet will not meet that. A documented, dated program will. ## Who qualifies for Wegovy for heart disease in Nebraska? An adult between 45 and 74 with a documented heart attack or stroke, or with artery disease in the legs that causes symptoms, shown by leg pain on walking with an ankle-brachial index under 0.85, a past artery procedure or an amputation from artery disease.[2] The person must not have diabetes and must have an A1C below 6.5%, and the BMI must reach 30, or 27 when a weight-related condition is also present.[2] The form also asks the prescriber to confirm the patient takes the heart medicines already prescribed.[2] The age window is stricter than the label, which sets no upper age for adults who have heart disease along with excess weight.[12] Someone who is 76 with a past heart attack meets the label but not Nebraska’s form. Renewal comes after six months and lasts 12; it needs a stable maintenance dose and a loss of 5% or more of starting weight, either newly reached or held since the first approval.[2] ## What does Nebraska ask for with Wegovy and MASH? Proof of the scarring stage, and recent proof. The fibrosis must be stage F2 or F3, confirmed by a FibroScan, magnetic resonance elastography or ELF blood test from the past six months, or a liver biopsy from the past 12 months.[2] An endocrinologist, gastroenterologist or liver specialist must prescribe it or be consulted, and Wegovy cannot be combined with Rezdiffra, the other MASH drug.[2] This is the one route open to people with type 2 diabetes, provided Ozempic has been tried first; [Nevada Medicaid’s MASH route](https://glpwatchdog.org/research/nevada-medicaid-glp1-coverage) sets no diabetes bar at all.[2] Nebraska Total Care sets the same condition and asks to see it in paid pharmacy claims.[5] Renewal needs fibrosis that has improved or held steady and no cirrhosis.[2] Our page on [semaglutide for MASH](https://glpwatchdog.org/research/glp1-and-fatty-liver-mash) covers the trial behind the label, which the FDA approved on an accelerated basis.[12] ## What does Nebraska require for Zepbound and sleep apnea? A long list. Beyond an AHI of at least 15 on a sleep study (or the same score on the related RDI or REI scales), a BMI of 30 or more and no diabetes, the patient must have tried both breathing-device therapy and an oral appliance, and each must have failed, been poorly tolerated, or been unsuitable.[3] The six-month weight program here also includes advice to avoid sleeping on the back and to avoid alcohol and sedatives at bedtime.[3] A sleep specialist must prescribe it or be consulted.[3] The patient must keep using PAP, which the form defines as at least four hours a night on at least 70% of nights for two months or more.[3] Central or mixed sleep apnea, major craniofacial abnormalities, or planned surgery for sleep apnea or obesity rule the request out.[3] Renewals run six months until the patient reaches 52 weeks on a maintenance dose of 10 or 15 mg, then 12 months, and each needs a lower apnea score than at baseline.[3] The label itself requires none of the device steps.[11] Our guide to [how Zepbound was tested for sleep apnea](https://glpwatchdog.org/research/zepbound-for-sleep-apnea) explains the trials. ## Does Nebraska Medicaid cover Ozempic for diabetes? Yes. Ozempic, Trulicity and Victoza are the preferred GLP-1s. They need a type 2 diabetes diagnosis and a failed or poorly tolerated trial of metformin, though people with diabetes and heart or artery disease can skip the metformin step.[4] Mounjaro and the Ozempic tablet are non-preferred: they need failures on two preferred GLP-1s, an A1C of 7 or higher and a metformin trial.[4] Rybelsus, listed as non-preferred in October, is not on the November 2026 list.[4] ## How do you file, and how do you appeal a denial? Fee-for-service prescribers fax the drug’s form, with the supporting records, to Prime Therapeutics at 866-759-4115; the help line is 800-241-8335.[2][3] Heritage Health members’ prescribers file with the member’s plan. Appeals depend on the plan type. A Heritage Health member first appeals to the plan, and federal rules give 60 days from the date on the denial notice to do so.[7] When the plan’s answer is still no, the member then has at least 90 and at most 120 days from the plan’s decision to ask the state for a fair hearing.[8] For fee-for-service members, federal rules cap the state’s deadline at 90 days from the date the notice is mailed.[9] The exact deadline is printed on the notice, so use that date. Our guide to [preparing a GLP-1 prior authorization appeal](https://glpwatchdog.org/research/glp1-prior-authorization-and-appeals) covers what to include, and the [Nebraska state page](https://glpwatchdog.org/states/nebraska) collects the main facts. ## What can you do if Nebraska Medicaid denies coverage? Paying out of pocket is the main fallback, because manufacturer copay cards exclude Medicaid members.[13] As of November 2026, Novo Nordisk’s self-pay price is $349 a month for most Wegovy pen doses, and the Wegovy pill starts at $149.[14] Lilly sells Zepbound for $299 at the starting dose and $399 at 5 mg, with $449 for higher doses when refills stay on schedule.[13] Read each offer’s terms on government insurance first. Our guide to [the least expensive GLP-1 options without coverage](https://glpwatchdog.org/research/cheapest-glp1-without-insurance) compares them. ## Frequently asked questions ### Does Nebraska Medicaid cover Wegovy for weight loss? No. Nebraska's pharmacy rules bar payment for drugs prescribed for weight control or appetite suppression. As of November 2026, Wegovy can be approved with prior authorization only to lower heart risk in adults aged 45 to 74 with past heart disease, or to treat MASH with F2 or F3 liver scarring. ### Does Nebraska Heritage Health cover Zepbound? Only for moderate to severe sleep apnea, under the state's criteria. The adult needs an AHI of 15 or more, a BMI of 30 or more, no diabetes, a sleep specialist, failed or unsuitable CPAP and oral appliance therapy, and six months in a supervised weight program. Nebraska Total Care follows the state rules; the other plans' forms may differ. ### Why does Nebraska limit Wegovy for heart disease to ages 45 to 74? The age range is written into Nebraska's prior authorization form and one Heritage Health plan's policy. The FDA label has no upper age limit for the heart indication, so a person older than 74 can meet the label but not the state's criteria. ### What is the six-month weight program Nebraska Medicaid requires? Every non-diabetes GLP-1 route requires at least six months of weight management supervised by a physician, nurse practitioner or physician assistant, with behavior change, a reduced-calorie diet and more physical activity. The sleep apnea route adds counseling on sleep position and bedtime alcohol and sedatives. ### Does Nebraska Medicaid cover Ozempic? Yes, for type 2 diabetes. Ozempic, Trulicity and Victoza are preferred and need a diabetes diagnosis plus a metformin trial, which is waived for people with diabetes and heart or artery disease. Ozempic is not covered for weight control. ## References 1. State of Nebraska 471 Neb. Admin. Code ch. 16, §008: Non-Covered Drugs. Legal Information Institute, Cornell Law School. 2026. https://www.law.cornell.edu/regulations/nebraska/471-Neb-Admin-Code-ch-16-SS-008 2. Nebraska Department of Health and Human Services Nebraska Medicaid Fee-For-Service Pharmacy Benefit Request for Prior Authorization: Wegovy (semaglutide), last reviewed January 2026. nebraska.fhsc.com. 2026. https://nebraska.fhsc.com/Downloads/NEfaxform_anti-obesity_Wegovy.pdf 3. Nebraska Medicaid Program Request for Prior Authorization: Anti-Obesity Medication (Zepbound), last revised July 1, 2025. nebraska.fhsc.com. 2025. https://nebraska.fhsc.com/Downloads/NEfaxform_anti-obesity_Zepbound.pdf 4. Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria, November 2026 (updated November 2, 2026). nebraska.fhsc.com. 2026. https://nebraska.fhsc.com/downloads/PDL/NE_PDL-20261101.pdf 5. Nebraska Total Care Clinical Policy NE.PMN.295: Semaglutide (Wegovy), Medicaid. nebraskatotalcare.com. 2026. https://www.nebraskatotalcare.com/content/dam/centene/Nebraska/policies/pharmacy-policies/NE.PMN.295_Semaglutide_Wegovy_02012026_508.pdf 6. Nebraska Department of Health and Human Services Heritage Health (Managed Care) Contacts. dhhs.ne.gov. 2026. https://dhhs.ne.gov/Pages/Heritage-Health-Contacts.aspx 7. Code of Federal Regulations 42 CFR 438.402: General requirements (managed care grievances and appeals). eCFR. 2026. https://www.ecfr.gov/current/title-42/chapter-IV/subchapter-C/part-438/subpart-F/section-438.402 8. Code of Federal Regulations 42 CFR 438.408: Resolution and notification of grievances and appeals. eCFR. 2026. https://www.ecfr.gov/current/title-42/chapter-IV/subchapter-C/part-438/subpart-F/section-438.408 9. Code of Federal Regulations 42 CFR 431.221: Request for hearing. eCFR. 2026. https://www.ecfr.gov/current/title-42/chapter-IV/subchapter-C/part-431/subpart-E/section-431.221 10. United States Code 42 U.S.C. §1396r-8: Payment for covered outpatient drugs (Social Security Act §1927). Legal Information Institute, Cornell Law School. 2026. https://www.law.cornell.edu/uscode/text/42/1396r-8 11. Eli Lilly and Company ZEPBOUND (tirzepatide) injection: prescribing information. DailyMed. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b 12. Novo Nordisk WEGOVY (semaglutide) injection and tablets: prescribing information. DailyMed. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b 13. Eli Lilly and Company Zepbound savings and self-pay options, with card terms. zepbound.lilly.com. 2026. https://zepbound.lilly.com/savings 14. Novo Nordisk Wegovy savings offer and self-pay pricing. novocare.com. 2026. https://www.novocare.com/obesity/products/wegovy/savings-offer.html --- Cite as: GLP Watchdog, Nora Bissett, "Does Nebraska Medicaid Cover Wegovy or Zepbound? Heritage Health GLP-1 Rules", published 2026-11-07. https://glpwatchdog.org/research/nebraska-medicaid-glp1-coverage Canonical HTML page: https://glpwatchdog.org/research/nebraska-medicaid-glp1-coverage Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.